Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial)

Andrea Schmid(University Hospital of Bern), Thomas Pabst(University Hospital of Bern), Gabriela M. Baerlocher(Terry Fox Research Institute), Behrouz Mansouri Taleghani(University of Bern), Peter M. Keller(University of Zurich), Beatrice U. Mueller, Dorothea Friess(University Hospital of Bern), Kurt Leibundgut(Swiss Red Cross)

Leukemia & lymphoma/Leukemia and lymphoma

June 2, 2014

10.3109/10428194.2014.927454

Cited by 17

Related Papers

Mutations in <i>TERT,</i> the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia

|New England Journal of Medicine|2005|717

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

|Leukemia|2012|417

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

|Leukemia|2017|339

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

|Journal of Clinical Oncology|2004|300

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

|Journal of Clinical Oncology|2013|299